Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27783112 | 1.00 | NFE2L2 (0.43) | NFE2L2KCNH2HTR2ACYP2A6CYP2B6 | |
| SCHEMBL15516669 | 0.78 | NFE2L2 (0.46) | NFE2L2KCNH2HTR2ACYP2A6CYP2B6 | |
| SCHEMBL114139 | 0.77 | — | — | |
| SCHEMBL29773863 | 0.75 | ALDH1A1 (0.45) | NFE2L2KCNH2HTR2AP4HTM | |
| SCHEMBL2641804 | 0.75 | CYP19A1 (0.48) | NFE2L2KCNH2HTR2A | |
| SCHEMBL2641872 | 0.75 | KMT2A (0.49) | NFE2L2CYP3A4CYP2C19 | |
| SCHEMBL18921524 | 0.75 | ALDH1A1 (0.45) | NFE2L2KCNH2HTR2AP4HTM | |
| SCHEMBL2641801 | 0.75 | CYP19A1 (0.48) | NFE2L2KCNH2HTR2A | |
| SCHEMBL18921523 | 0.75 | ALDH1A1 (0.45) | NFE2L2KCNH2HTR2AP4HTM | |
| SCHEMBL2641876 | 0.75 | KMT2A (0.49) | NFE2L2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890676-B1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2018-12-05 | — | — | EP | disclosed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-9670195-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-06-06 | — | — | US | disclosed |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2017-04-20 | — | — | US | disclosed |
| US-9522883-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2016-12-20 | — | — | US | disclosed |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| US-20150218097-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-08-06 | — | — | US | disclosed |
| US-20150218147-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-08-06 | — | — | US | disclosed |
| EP-2890678-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890675-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890679-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890676-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014032187-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032185-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032184-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032188-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | NFE2L2 2756/4885KCNH2 4569/4885HTR2A 4296/4885 |
| US-20150218097-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | GAA, ENGASE, OGA | NFE2L2 1555/4885KCNH2 3610/4885HTR2A 2904/4885 |
| US-20150299122-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | NFE2L2 2756/4885KCNH2 4569/4885HTR2A 4296/4885 |
| US-20150218147-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | NFE2L2 2756/4885KCNH2 4569/4885HTR2A 4296/4885 |
| US-20170107180-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | NFE2L2 2756/4885KCNH2 4569/4885HTR2A 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.